New Phase 3 trials registered, week of November 16, 2026: 2 industry trials
Industry sponsors registered 2 Phase 3 trials on ClinicalTrials.gov so far in the week of November 16 to 22, 2026. They plan to enroll 10,120 participants in all; the largest, Novartis Pharmaceuticals' PINNACLE-MI trial, plans to enroll 10,000.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, November 22, 2026.
The trials
- Novartis registers Phase 3 trial of Pacibekitug in patients after a Myocardial Infarction. Sponsor: Novartis Pharmaceuticals. Condition: Myocardial Infarction. Intervention: Pacibekitug. Phase: Phase 3. Planned enrollment: 10,000. Planned primary completion: October 2030. First posted November 16, 2026. Record: NCT07938411 (PINNACLE-MI).
- Dexa Medica Group registers completed Phase 3 trial of DLBS3233 in prediabetes. Sponsor: Dexa Medica Group. Condition: Prediabetes. Interventions: DLBS3233, Metformin XR. Phase: Phase 3. Enrollment: 120 (actual). Primary completion: October 2026. First posted November 16, 2026. Record: NCT07937449.
By the numbers
- Trials: 2, from 2 lead sponsors.
- Planned enrollment: 10,120 in all across 2 trials; median 5,060 per trial.
- Largest: Novartis Pharmaceuticals' PINNACLE-MI trial, 10,000. Smallest: Dexa Medica Group's DLBS3233 trial, 120.
- Phases as registered: 2 Phase 3.
- Planned primary completion: from October 2026 to October 2030.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Planned figures are the sponsor's estimates at registration.